Announcement PDF ABN 16 165 160 841 ASX RELEASE 16 April 2024 Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27 million • Amplia is developing a pipeline of small molecule inhibitors of Focal Adhesion Kinase (FAK) - a clinically validated target in cancer • Amplia’s lead compound narmafotinib (AMP945) is the best-in-class FAK inhibitor in development • Promising clinical safety and tolerability data positions narmafotinib as the preferred agent to enhance the activity of drugs that are currently standard-of-care, for the treatment of pancreatic cancer and other solid tumours • The capital raising consists of a two (2) for five (5), fully underwritten pro-rata nonrenounceable Entitlement Offer to raise $4.27m • The New Shares issued under the Entitlement Offer are priced at $0.055 each • Proceeds from the Entitlement Offer will be used to: • - Provide sufficient funding to undertake the Interim Analysis for the ongoing Phase 2a ACCENT trial - Undertake production of additional narmafotinib, and manufacture a further batch of 25,000 capsules - Support a pilot Investigator Initiated Trial in ovarian cancer The Entitlement Offer has received significant support from new and existing institutional investors and the Company’s Directors The Entitlement Offer The Company is undertaking a fully underwritten two (2) for five (5), pro-rata non-renounceable Entitlement Offer to raise $4.27m via the issue of 77.6 million New Shares to Eligible Shareholders in Australia and New Zealand (Entitlement Offer). Eligible Shareholders under the Entitlement Offer will be able to subscribe for two (2) New Shares for every five (5) shares held (Entitlements) at 7:00pm (Melbourne time) on Friday 19 April 2024 (Record Date) at the Offer Price of $0.055 per New Share. The Entitlement Offer is non-renounceable which means that Entitlements are not transferable and cannot be traded on the ASX (or any other exchange) or transferred privately. The Offer Price of $0.055 per New Share represents a discount of: • 35.3% to the last traded price on Thursday 11 April 2024; • 29.6% to the volume weighted average price of Amplia shares for the 15 business days ending on Thursday 11 April 2024; and • 28.0% to the theoretical ex rights price (TERP) of Amplia shares. Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com Eligible Shareholders with registered addresses in Australia and New Zealand will be entitled to participate in the Entitlement Offer, which will open on Wednesday 24 April 2024 and will close at 5:00pm (Melbourne time) on Wednesday 8 May 2024 (Closing Date) unless extended. Offer Booklet An Offer Booklet containing information in respect of the Entitlement Offer will be lodged with ASX on Wednesday 24 April 2024. The Offer Booklet and Entitlement and Acceptance Form will be made available to Eligible Shareholders on Wednesday 24 April 2024. Eligible Shareholders should read the Offer Booklet in full before deciding whether to subscribe for New Shares. Eligible Shareholders will be able to access a copy of the Offer Booklet via Computershare’s Investor Centre at www.investorcentre.com/au . Eligible Shareholders will need to provide their Securityholder Reference Number (SRN) or Holder Identification Number (HIN) and postcode to access the Offer Booklet and the accompanying Entitlement and Acceptance Form and participate in the Entitlement Offer. Top-up Facility The Entitlement Offer will include a top-up facility, under which Eligible Shareholders who have taken up their full Entitlement under the Entitlement Offer can apply to take up additional New Shares in excess of their Entitlements, that have not been taken up by other Shareholders (Top-up Facility). Eligible Shareholders who subscribe for their full Entitlement will be entitled to subscribe for additional New Shares representing up to 100% of their Entitlement under the Top-up Facility. Applications will be allocated on a pro rata basis, subject to applicable laws and scale back in accordance with the policy described in the Offer Booklet. Director Participation The directors of the Company have committed to take a total of ~$228,000 in the Entitlement Offer comprised as follows: • Managing Director and CEO, Dr Chris Burns, has committed to take up 60% of his entitlements under the Entitlement Offer, totalling ~$33,400; • Director, Jane Bell, has committed to take 100% of her entitlements under the Entitlement Offer, totalling ~$44,600; and • Director, Dr Robert Peach, has committed to subscribe for ~$150,000 of general subunderwriting in the Offer, which represents ~4.2x his entitlement. Underwriting Arrangements The Entitlement Offer will be fully underwritten by the lead manager of the capital raise, Taylor Collison Limited (Underwriter), pursuant to an underwriting agreement with the Company dated Tuesday 16 April 2024 (Underwriting Agreement). Further details regarding the Underwriting Agreement, and Dr Robert Peach’s sub-underwriting arrangements, can be found in the investor presentation lodged with ASX on 16 April 2024. 2 Use of Funds The Company intends to use current cash and the funds raised from the Entitlement Offer for the following purposes: Purpose Amount Pre-clinical studies (cancer) $0.15m Phase 1 (Pilot Investigator Initiated) clinical trial – Ovarian Cancer $0.15m Phase 2a clinical trial – Pancreatic Cancer $2.04m Additional Drug capsule manufacture $1.35m IP and licences $0.1m Cash costs of the Entitlement Offer $0.33m Working capital $0.15m TOTAL $4.27m Indicative Timetable The Capital Raising will be conducted according to the following indicative timetable: Event Date (2024) Trading Halt commenced Friday 12 April Capital Raising announced, trading halt lifted Tuesday 16 April Record Date for Entitlement Offer (AEST 7.00pm) Friday 19 April Entitlement Offer opens Wednesday 24 April Entitlement Offer closes Wednesday 8 May Announcement of results of Entitlement Offer Wednesday 15 May Issue of New Shares under the Entitlement Offer Wednesday 15 May Trading of New Shares issued under the Entitlement Offer Thursday 16 May This Timetable is indicative only and subject to change. The Company may vary these dates, in consultation with the Underwriter, subject to the ASX Listing Rules. An extension of the Entitlement Offer Closing Date will delay the anticipated date for issue of the New Shares. The Directors also reserve the right to withdraw or not proceed with the Entitlement Offer at any time before the allotment and issue of the New Shares. In that event, the relevant Application Monies will be returned in full to Applicants (without interest). Current Optionholders Existing optionholders may only participate in the Entitlement Offer in respect of their vested options if those options have been exercised and Shares allotted by the Record Date. Optionholders must 3 therefore exercise their options prior to 7:00pm on Friday 19 April 2024 if they intend to participate in the Entitlement Offer in respect of those vested options. Further Information For further information on the Entitlement Offer, you can contact the Company Secretary by email on info@ampliatx.com . If you have any further questions, you should contact your stockbroker, solicitor, accountant or other professional advisor. About the ACCENT Trial The protocol for the ACCENT trial is entitled ‘A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients’. The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b) determined an optimal dose of narmafotinib (AMP945) by assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of narmafotinib when dosed in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. This second stage (Phase 2a), of the trial is designed to assess efficacy of narmafotinib in combination with gemcitabine and Abraxane. The primary endpoints are Objective Response Rate (ORR) and Duration on Trial (DOT) with secondary endpoints being Progression Free Survival (PFS) and Overall Survival (OS). Safety and tolerability will continue to be assessed. More information about the ACCENT trial, including a list of participating sites, can be found via the Amplia Therapeutics website and at ClinicalTrials.gov under the identifier NCT05355298. The Company will provide further updates on the trial as recruitment proceeds. This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn. 4